NASDAQ · DHR
Healthcare · Medical - Diagnostics & Research
$209.36
Up+$6.04 (+2.97%)
Updated Sep 16, 2026, 11:30 AM
SID Score
5.8/10
Composite research score
Smart Money
51/100
Neutral
Price performance
1M range · 20 trading sessions · Daily adjusted prices
DHR closed at $209.36 after 20 trading sessions, up 4.90% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 15, 2026 | $203.08 | $209.55 | $202.6201 | $209.36 | 3.51M |
| Sep 14, 2026 | $202.48 | $203.81 | $199.09 | $203.25 | 3.43M |
| Sep 11, 2026 | $201.99 | $202.68 | $199.16 | $200.14 | 3.63M |
| Sep 10, 2026 | $202.33 | $203.10 | $200.34 | $200.53 | 3.02M |
| Sep 9, 2026 | $206.00 | $206.05 | $201.95 | $204.85 | 2.77M |
| Sep 8, 2026 | $205.00 | $207.84 | $202.12 | $205.23 | 3.28M |
| Sep 4, 2026 | $207.19 | $208.70 | $205.23 | $207.66 | 2.9M |
| Sep 3, 2026 | $210.51 | $213.13 | $206.05 | $211.03 | 2.42M |
| Sep 2, 2026 | $207.77 | $212.7793 | $206.10 | $209.91 | 2.95M |
| Sep 1, 2026 | $214.74 | $215.00 | $206.55 | $206.93 | 3.15M |
| Aug 31, 2026 | $213.45 | $215.385 | $212.22 | $213.56 | 3.61M |
| Aug 28, 2026 | $215.10 | $217.04 | $212.8502 | $216.07 | 2.86M |
| Aug 27, 2026 | $214.78 | $218.57 | $213.092 | $215.68 | 2.93M |
| Aug 26, 2026 | $213.23 | $216.8499 | $212.81 | $215.36 | 2.53M |
| Aug 25, 2026 | $213.88 | $216.77 | $212.24 | $215.97 | 2.34M |
| Aug 24, 2026 | $218.33 | $218.34 | $213.88 | $215.11 | 2.51M |
| Aug 21, 2026 | $215.58 | $220.25 | $213.46 | $218.85 | 4.7M |
| Aug 20, 2026 | $210.12 | $220.67 | $208.21 | $215.91 | 5.5M |
| Aug 19, 2026 | $203.10 | $212.19 | $202.905 | $211.50 | 5.25M |
| Aug 18, 2026 | $203.97 | $204.23 | $199.49 | $199.58 | 2.29M |
The latest Smart Investors Daily articles mentioning DHR.
DHR research
Company profile and research snapshot.
In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Then, through a series of mergers, acquisitions, and divestitures, Danaher now focuses primarily on manufacturing scientific instruments and consumables in the life sciences and diagnostic industries after the late 2023 divestiture of its environmental and applied solutions group, Veralto.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Jul 22, 2026 | RBC Capital | Outperform | — |
| Jul 22, 2026 | Guggenheim | Buy | — |
| Jul 22, 2026 | Stifel | Buy | — |
| Jul 22, 2026 | TD Cowen | Buy | — |
| Jul 22, 2026 | Wells Fargo | Equal-Weight | — |
Generated Sep 15, 2026, 9:08 PM
Danaher Corporation gained 2.97% today, climbing $6.04 as investors reassess the company's relative value positioning in the market. The modest but positive movement suggests renewed investor interest in the diversified conglomerate, particularly as analysts compare its valuation metrics against peers like ELV.
Bottom line: Danaher's 3% gain appears driven by renewed valuation interest rather than fundamental news, positioning the stock as an attractive entry point for value-conscious investors. While the lack of major catalysts presents near-term risks, the company's defensive characteristics and operational excellence provide a solid foundation for long-term investors to monitor. Watch for upcoming earnings reports and management commentary on capital allocation strategy to confirm whether this valuation re-rating has staying power.
Yahoo · Sep 16, 2026
Donaldson (DCI) has gained 9.1% over the past twelve months and still trades about 20% below its 52-week high. The filtration company behind those numbers sells replacement parts into equipment already in service, and the cash from that stream has been steadily shrinking its share count. The shrinking count is the case for buying the pullback. It is also the part that goes quiet in fiscal 2027.
Yahoo · Sep 15, 2026
Danaher Corporation (NYSE: DHR) announced today that its Board of Directors has approved a regular quarterly cash dividend of $0.40 per share of its common stock, payable on October 30, 2026 to holders of record on September 30, 2026.
Yahoo · Sep 15, 2026
ELV vs. DHR: Which Stock Is the Better Value Option?
SeekingAlpha · Sep 10, 2026
Third Pointâs Q2 2026 13F: portfolio doubled to $4.68B as WBD becomes top holding; new buys include Keysight, Block; exits Meta/Nvidia. See more here.
Interpretive context generated from the platform’s current data sources.
Danaher Corporation shares closed at $209.29, declining 1.12% in the most recent trading session, per SID market data. Over the trailing one-month period, DHR has gained 3.41%, while the three-month return stands at a more substantial 15.6%, indicating meaningful upside momentum in the intermediate term. However, the trailing twelve-month return of -9.9% reflects broader underperformance relative to the healthcare sector. Technically, the stock trades above both its 50-day moving average of $202.80 and its 200-day moving average of $198.93, suggesting the recent rally has shifted the medium-term trend higher, according to Massive/Polygon data. The 14-day relative strength index sits at 40.5, placing DHR in neutral territory with no immediate overbought or oversold signals. Average daily volume registers at approximately 4.18 million shares, supporting adequate liquidity. The stock carries a beta of 0.923, indicating slightly lower volatility than the broader market.
Danaher Corporation currently commands a market capitalization of approximately $166.5 billion, positioning it among the largest healthcare conglomerates globally, per SID market data. The stock trades at a price-to-earnings ratio of 47.14, a significant premium to the broader S&P 500 average, reflecting the market's expectations for sustained long-term earnings growth. However, the PEG ratio of 14.87 suggests that the current valuation substantially exceeds what near-term growth rates alone would justify, according to SEC filings and consensus growth estimates. The price-to-book ratio stands at 3.23, consistent with Danaher's asset-light, acquisition-driven business model. The company offers a modest dividend yield of 0.53%, prioritizing capital allocation toward strategic acquisitions and reinvestment over shareholder distributions. Taken together, these valuation metrics indicate that DHR is priced for significant future earnings expansion, particularly as the life sciences and diagnostics end markets recover from pandemic-era normalization headwinds.
Danaher Corporation registers a composite smart money score of 51 out of 100, reflecting a neutral overall signal, per SID market data. The institutional component scores a perfect 25 out of 25, indicating exceptionally strong positioning among large fund managers and signaling broad institutional confidence in the company's long-term fundamentals. In contrast, the insider trading component scores just 4.9 out of 25, despite notable recent activity — SEC Form 4 filings reveal 20 insider transactions over the past 90 days, comprising 17 purchases and only 3 sales. This heavily buy-skewed ratio suggests corporate insiders view current price levels favorably. The dark pool activity score stands at 8.5 out of 25, indicating moderate but unremarkable off-exchange institutional volume. Congressional trading activity scores 12.8 out of 25, per 13F institutional filings, reflecting middling legislative interest. The divergence between the maximum institutional score and the below-average insider score creates a mixed but cautiously constructive positioning profile for DHR among sophisticated market participants.
Danaher Corporation has demonstrated a consistent pattern of earnings outperformance across its most recent reporting periods, according to company earnings reports. In the most recent quarter, DHR reported earnings per share of $1.94 against a consensus estimate of $1.84, representing a positive surprise of $0.10. The prior quarter delivered an even stronger beat, with actual EPS of $2.06 versus the $1.94 estimate, a $0.12 upside surprise. The quarter before that saw EPS of $2.23 compared to the $2.17 estimate, a $0.06 positive variance. This three-quarter streak of beats signals disciplined execution and potentially conservative guidance practices. Looking ahead, analyst estimates project EPS of approximately $2.17 for the upcoming quarter, per consensus data. The sequential decline in reported EPS from $2.23 to $2.06 to $1.94 warrants monitoring, though the sustained ability to exceed estimates provides a degree of confidence in management's operational control and forward visibility.
Wall Street consensus on Danaher Corporation skews decidedly bullish, with the most recent wave of analyst updates reinforcing existing positive outlooks, per Wall Street analyst reports. On July 22, 2026, four of five covering analysts maintained favorable ratings: TD Cowen, Stifel, and Guggenheim each reiterated Buy recommendations, while RBC Capital maintained its Outperform rating. Wells Fargo was the sole neutral voice, reaffirming its Equal-Weight stance. Notably, none of the five analysts altered their prior ratings, suggesting the latest quarterly results met or aligned with expectations without catalyzing meaningful reassessment. The 4-to-1 ratio of bullish-to-neutral ratings reflects broad confidence in Danaher's portfolio transformation following the Veralto separation and its positioning in high-growth life sciences and diagnostics markets, according to SID consensus data. The absence of any Sell or Underperform ratings among recent coverage updates underscores a uniformly constructive view, though the elevated valuation multiples may constrain the degree of additional upside analysts are willing to project.
The latest Smart Investors Daily articles mentioning DHR.
